Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 1.00 |
| ▸ | RAB9A | P51151 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | PLAU | P00749 | 2/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31680508 | 0.96 | NPC1 (0.93) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL5426350 | 0.90 | NPC1 (0.82) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1918108 | 0.90 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL29420092 | 0.90 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL12218147 | 0.88 | RAB9A (0.79) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL5427878 | 0.88 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL28187512 | 0.88 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL6799157 | 0.87 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL7296804 | 0.87 | SMN1; SMN2 (0.77) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL16675159 | 0.86 | NPC1 (0.83) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885SMN1; SMN2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.